Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Mondello, Patrizia, Brea, Elliott J., De Stanchina, Elisa, Toska, Eneda, Chang, Aaron Y., Fennell, Myles, Seshan, Venkatraman, Garippa, Ralph, Scheinberg, David A., Baselga, José, Wendel, Hans-Guido, Younes, Anas
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358483/
https://ncbi.nlm.nih.gov/pubmed/28352655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.90196
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars